SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Astellas Pharma Inc. ALPMY OTC

Other OTC • Healthcare • Drug Manufacturers - General • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Astellas Pharma Inc. (ALPMY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $16.02. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $1.9T, +14%/yr average growth. Net income is $50.7B, growing at +31.5%/yr. Net profit margin is 2.7% (thin). Gross margin is 81.7% (+3.4 pp trend).

Balance sheet: total debt is $831.4B against $1.5T equity (Debt-to-Equity (D/E) ratio 0.55, moderate). Current ratio is 1.13 (adequate). Debt-to-assets is 24.9%. Total assets: $3.3T.

Analyst outlook: 2 / 3 analysts rate ALPMY as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 33/100 (Fail), Moat 88/100 (Pass), Future 55/100 (Partial), Income 30/100 (Fail).

ALPMY SharesGrow Score Overview

71/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 88/100

Gross margin is + market cap

FUTURE 55/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALPMY

ALPMY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ALPMY: +14%/yr revenue is, +31.5%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

ALPMY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet ALPMY: Debt-to-Equity (D/E) ratio 0.55 (moderate), Current ratio is 1.13 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ALPMY: Gross margin is 81.7% (+3.4 pp trend), $29B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 88/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 3 analysts rate ALPMY as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ALPMY: Net profit margin is 2.7%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range8.37-17.35

Volume42.22K

Avg Volume (30D)155.84K

Market Cap$28.7B

Beta (1Y)0.15

Dividend Yield$0.5100

Share Statistics

EPS (TTM)28.35

Shares Outstanding$1.8B

IPO Date2009-12-29

Employees14,754

CEONaoki Okamura

Financial Highlights & Ratios

Revenue (TTM)$1.91T

Gross Profit$1.56T

EBITDA$248.05B

Net Income$50.75B

Operating Income$41.04B

Total Cash$218.31B

Total Debt$831.43B

Net Debt$643.05B

Total Assets$3.34T

Price / Earnings (P/E)0.6

Price / Sales (P/S)0.02

Analyst Forecast

Rating ConsensusBuy

Analysts Covering3

Buy 67% Hold 33% Sell 0%

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINUS04623U1025

Price Chart

ALPMY

Astellas Pharma Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - General

8.37 52WK RANGE 17.35

People Also View

AstraZeneca PLC

Otsuka Holdings Co., Ltd.

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message